NO955352L - Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse - Google Patents

Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse

Info

Publication number
NO955352L
NO955352L NO955352A NO955352A NO955352L NO 955352 L NO955352 L NO 955352L NO 955352 A NO955352 A NO 955352A NO 955352 A NO955352 A NO 955352A NO 955352 L NO955352 L NO 955352L
Authority
NO
Norway
Prior art keywords
preparation
pct
acid ester
phosphoric acid
methyl phosphoric
Prior art date
Application number
NO955352A
Other languages
English (en)
Other versions
NO319860B1 (no
NO955352D0 (no
Inventor
Eugen Uhlmann
Chris Meier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO955352D0 publication Critical patent/NO955352D0/no
Publication of NO955352L publication Critical patent/NO955352L/no
Publication of NO319860B1 publication Critical patent/NO319860B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19955352A 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse NO319860B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4321946A DE4321946A1 (de) 1993-07-01 1993-07-01 Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP1994/002121 WO1995001363A1 (de) 1993-07-01 1994-06-29 Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung

Publications (3)

Publication Number Publication Date
NO955352D0 NO955352D0 (no) 1995-12-29
NO955352L true NO955352L (no) 1996-02-14
NO319860B1 NO319860B1 (no) 2005-09-26

Family

ID=6491730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955352A NO319860B1 (no) 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse

Country Status (13)

Country Link
US (1) US6028182A (no)
EP (1) EP0707591B1 (no)
JP (1) JP3831407B2 (no)
AT (1) ATE206130T1 (no)
AU (1) AU698928B2 (no)
CA (1) CA2165971C (no)
DE (2) DE4321946A1 (no)
DK (1) DK0707591T3 (no)
ES (1) ES2165391T3 (no)
FI (1) FI115399B (no)
NO (1) NO319860B1 (no)
PT (1) PT707591E (no)
WO (1) WO1995001363A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DK0739898T3 (da) * 1995-03-13 2001-12-10 Aventis Pharma Gmbh Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
WO1998028317A2 (en) * 1996-12-24 1998-07-02 Ribozyme Pharmaceuticals, Inc. Synthesis of nucleosides and polynucleotides
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US20020119178A1 (en) * 2001-02-23 2002-08-29 Luc Levesque Drug eluting device for treating vascular diseases
GB0110732D0 (en) * 2001-05-02 2001-06-27 Psl Technology Ltd Apparatus and method
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2006515277A (ja) 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Ｃ型肝炎ウィルス感染の処置および予防に関する方法および製品
EP1720568A2 (en) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
ES2553284T5 (es) 2006-02-15 2021-08-31 Rechtsanwalt Thomas Beck Composiciones y procedimientos para formulaciones de oligonucleótidos
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2160199A2 (en) * 2007-05-17 2010-03-10 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
CN101820908A (zh) 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
JP6084770B2 (ja) * 2008-06-26 2017-02-22 プロリンクス エルエルシー 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
HRP20181039T1 (hr) 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
JP6885867B2 (ja) 2014-12-31 2021-06-16 チェックメイト ファーマシューティカルズ， インコーポレイテッド 組合せ腫瘍免疫療法
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US12084655B2 (en) 2018-04-09 2024-09-10 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
IL320955A (en) 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025238502A1 (en) 2024-05-14 2025-11-20 Pfizer Inc. Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010140A1 (en) * 1991-11-21 1993-05-27 Pharmagenics, Inc. Oligonucleotides having modified anionic moieties

Also Published As

Publication number Publication date
NO319860B1 (no) 2005-09-26
FI956341A0 (fi) 1995-12-29
NO955352D0 (no) 1995-12-29
DK0707591T3 (da) 2002-01-21
PT707591E (pt) 2002-03-28
ES2165391T3 (es) 2002-03-16
FI115399B (fi) 2005-04-29
AU698928B2 (en) 1998-11-12
CA2165971C (en) 2006-05-30
ATE206130T1 (de) 2001-10-15
CA2165971A1 (en) 1995-01-12
US6028182A (en) 2000-02-22
AU7073594A (en) 1995-01-24
EP0707591B1 (de) 2001-09-26
JPH08512039A (ja) 1996-12-17
DE59409880D1 (de) 2001-10-31
DE4321946A1 (de) 1995-01-12
JP3831407B2 (ja) 2006-10-11
WO1995001363A1 (de) 1995-01-12
EP0707591A1 (de) 1996-04-24
FI956341L (fi) 1996-02-19

Similar Documents

Publication Publication Date Title
NO955352L (no) Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
HU9603592D0 (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
EP0948327A4 (en) ANTIDIABETIC AGENTS
IT1270260B (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
PL300328A1 (en) Substituted cyclohexane derivatives for treating diseases
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
AU686197B2 (en) Use of coumarins and carbostyrils as PLA2-inhibitors, new coumarins and carbostyrils, process for preparing the same and medicaments
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
ATE123773T1 (de) 1,3,5-triazin-2,4,6-tris- alkylaminocarbonsäureaminoester, diese enthaltende biozide mittel sowie verfahren zu ihrer herstellung.
TW261614B (no)
DK0668852T3 (da) Substituerede orthoethenylphenyleddikesyrederivater
EP0653206A4 (en) ANTI-HIV ACTIVE SUBSTANCE.
PL355763A1 (en) Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same